Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100
| dc.contributor.author | Reck, M. | |
| dc.contributor.author | Barlesi, F. | |
| dc.contributor.author | Yang, , J. C.-H. | |
| dc.contributor.author | Westeel, V. | |
| dc.contributor.author | Felip, E. | |
| dc.contributor.author | Ozguroglu, M. | |
| dc.contributor.author | Dols, M. Cobo | |
| dc.contributor.author | Sullivan, R. | |
| dc.contributor.author | Kowalski, D. | |
| dc.contributor.author | Andric, Z. | |
| dc.contributor.author | Lee, D. H. | |
| dc.contributor.author | Sezer, A. | |
| dc.contributor.author | Shamrai, V. | |
| dc.contributor.author | Szalai, Z. | |
| dc.contributor.author | Wang, X. | |
| dc.contributor.author | Xiong, H. | |
| dc.contributor.author | Jacob, N. | |
| dc.contributor.author | Mehr, K. Tadjalli | |
| dc.contributor.author | Park, K. | |
| dc.date.accessioned | 2022-11-04T10:13:33Z | |
| dc.date.available | 2022-11-04T10:13:33Z | |
| dc.date.issued | 2022 | |
| dc.identifier.endpage | 39 | en_US |
| dc.identifier.issn | 1556-0864 | en_US |
| dc.identifier.issue | 9 | en_US |
| dc.identifier.startpage | 39 | en_US |
| dc.identifier.uri | http://hdl.handle.net/11727/8005 | |
| dc.identifier.volume | 17 | en_US |
| dc.identifier.wos | 000858678100062 | en_US |
| dc.language.iso | eng | en_US |
| dc.relation.journal | JOURNAL OF THORACIC ONCOLOGY | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | avelumab | en_US |
| dc.subject | NSCLC | en_US |
| dc.subject | first-line | en_US |
| dc.title | Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100 | en_US |
| dc.type | Conference Object | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: